SRC and ovarian cancer: Notable, bardoxolone methyl enhanced the cytotoxic effects of chemotherapeutics paclitaxel, in the paclitaxel-resistant ovarian cancer cell line OVCAR8(TR), and cisplatin, in the cisplatin-resistant ovarian cancer cell line A2780cp70, thus suggesting that bardoxolone methyl interferes with signaling through multiple kinases involved in the IL-6-Stat3 and Src pathways, likely by targeting several points within these signaling networks [105].